Citius Oncology, Inc. (CTOR) company profile

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its primary approved product is LYMPHIR (denileukin diftitox-cdxl), an engineered interleukin-2 diphtheria toxin fusion protein. The medication is designed for adult patients suffering from persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. LYMPHIR operates through a dual mechanism that delivers cytotoxic diphtheria toxin directly to cells expressing interleukin-2 receptors while simultaneously depleting immunosuppressive regulatory T cells.

The company focuses its direct commercialization activities within the United States, utilizing a specialized oncology sales team aimed primarily at major cancer centers. For markets outside the United States, the business establishes international commercial partnerships. Headquartered in Cranford, New Jersey, the company also evaluates combination immuno-oncology therapies through clinical investigations in clinical trial sites across the United States.

Summary of the business section of Citius Oncology's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Each unit has an offering price of $10.00 and consists of one of our ordinary shares and one right as described in more detail in this prospectus.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.